News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
261,411 Results
Type
Article (13603)
Company Profile (110)
Press Release (247698)
Section
Business (87995)
Career Advice (465)
Deals (15334)
Drug Delivery (64)
Drug Development (36534)
Employer Resources (49)
FDA (6269)
Job Trends (6189)
News (150096)
Policy (14011)
Tag
Academia (436)
Alliances (23105)
Alzheimer's disease (351)
Approvals (6263)
Artificial intelligence (61)
Bankruptcy (143)
Best Places to Work (4330)
Biotechnology (44)
Breast cancer (42)
Cancer (315)
Career advice (408)
Cell therapy (44)
Clinical research (30405)
Collaboration (156)
Compensation (62)
COVID-19 (747)
C-suite (52)
Data (343)
Diabetes (53)
Diagnostics (1238)
Drug pricing (57)
Earnings (31565)
Employer resources (43)
Events (36768)
Executive appointments (173)
FDA (6449)
Funding (108)
Gene therapy (59)
GLP-1 (292)
Government (1267)
Healthcare (3526)
Infectious disease (765)
Inflammatory bowel disease (46)
Interviews (58)
IPO (5822)
Job creations (2049)
Job search strategy (375)
Layoffs (167)
Legal (3413)
Lung cancer (46)
Manufacturing (99)
Medical device (1265)
Medtech (1267)
Mergers & acquisitions (9547)
Metabolic disorders (168)
Neuroscience (449)
NextGen Class of 2024 (1587)
Non-profit (599)
Northern California (434)
Obesity (101)
Opinion (109)
Patents (53)
People (28479)
Pharmaceutical (64)
Phase I (7904)
Phase II (12859)
Phase III (11554)
Pipeline (183)
Policy (45)
Postmarket research (1399)
Preclinical (3165)
Radiopharmaceuticals (116)
Rare diseases (90)
Real estate (2629)
Regulatory (9822)
Research institute (564)
Resumes & cover letters (56)
Southern California (435)
Startups (1630)
United States (4280)
Vaccines (112)
Weight loss (78)
Date
Today (46)
Last 7 days (273)
Last 30 days (1266)
Last 365 days (12714)
2024 (11623)
2023 (14248)
2022 (19565)
2021 (20076)
2020 (19042)
2019 (14909)
2018 (11728)
2017 (13898)
2016 (13141)
2015 (15487)
2014 (12423)
2013 (10595)
2012 (11398)
2011 (11928)
2010 (10890)
Location
Africa (312)
Arizona (42)
Asia (19795)
Australia (2560)
California (1008)
Canada (600)
China (111)
Colorado (42)
Connecticut (42)
Europe (38801)
Florida (152)
Illinois (111)
Indiana (86)
Japan (43)
Kansas (51)
Maryland (155)
Massachusetts (881)
Minnesota (56)
New Jersey (422)
New York (279)
North Carolina (278)
Northern California (434)
Pennsylvania (286)
South America (499)
Southern California (435)
Texas (138)
Virginia (41)
Washington State (71)
261,411 Results for "jazz pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Lung cancer
Jazz Touts Survival Benefit for First-Line Maintenance Therapy in SCLC
Jazz Pharmaceuticals contends that its alkylating agent Zepzelca significantly improved both overall survival and progression-free survival in patients with extensive-stage small cell lung cancer, when used as a front-line maintenance therapy with Roche’s Tecentriq.
October 16, 2024
·
2 min read
·
Tristan Manalac
Biotech Bay
Jazz Pharmaceuticals to Participate in Upcoming June 2024 Investor Conferences
Jazz Pharmaceuticals plc announced that Company management will participate in the following investor conferences.
May 29, 2024
·
1 min read
Drug Development
Jazz’s Tremor Drug Candidate Flops in Phase II Study, Misses Primary Endpoint
Jazz Pharmaceuticals’ calcium channel modulator suvecaltamide in a mid-stage trial was unable to significantly lower tremor burden in patients with essential tremor, the company reported Thursday.
June 21, 2024
·
2 min read
·
Tristan Manalac
Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the BofA Securities 2024 Global Health Care Conference on Wednesday, May 15, 2024, in Las Vegas.
May 1, 2024
·
1 min read
Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024
Jazz Pharmaceuticals pl the 38th annual meeting of the Associated Professional Sleep Societies being held June 1-5, 2024, in Houston, Texas.
May 30, 2024
·
20 min read
Drug Development
Jazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 2b clinical trial (NCT05122650) evaluating the efficacy and safety of suvecaltamide (JZP385), an investigational, highly selective and state-dependent modulator of T-type calcium channels, in adult patients with essential tremor (ET).
June 20, 2024
·
6 min read
Business
Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2024 and affirmed guidance for 2024.
May 1, 2024
·
30 min read
Business
Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 first quarter financial results on Wednesday, May 1, 2024, after the close of the U.S. financial markets.
April 17, 2024
·
2 min read
Business
Jazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced that Philip Johnson has been appointed Executive Vice President and Chief Financial Officer, effective March 1, 2024.
February 21, 2024
·
4 min read
Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present or publish eight abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4, 2024 in Chicago.
April 24, 2024
·
17 min read
1 of 26,142
Next
